Bank of Nova Scotia lessened its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 25.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 29,551 shares of the medical instruments supplier's stock after selling 10,135 shares during the period. Bank of Nova Scotia's holdings in Becton, Dickinson and Company were worth $4,472,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,704 shares of company stock worth $1,963,618 in the last quarter. Company insiders own 0.40% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on BDX shares. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a research report on Thursday, August 13th. The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a research note on Wednesday, May 27th. Weiss Ratings reissued a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Barclays raised their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $185.67.
View Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Price Performance
Shares of BDX opened at $189.87 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The firm has a 50-day simple moving average of $163.37 and a 200-day simple moving average of $160.60. The company has a market capitalization of $52.32 billion, a price-to-earnings ratio of 57.19, a price-to-earnings-growth ratio of 13.44 and a beta of 0.19.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is 126.51%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
